| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Modalis Therapeutics Corp
Modalis Therapeutics Corp
TSE:4883
Modalis Therapeutics Corp
Capital Expenditures
Modalis Therapeutics Corp
Capital Expenditures Peer Comparison
2160
4587
4974
2929
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Modalis Therapeutics Corp
TSE:4883
|
Capital Expenditures
-¥39.7m
|
CAGR 3-Years
64%
|
CAGR 5-Years
-136%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Capital Expenditures
-¥1.9B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-25%
|
|
|
PeptiDream Inc
TSE:4587
|
Capital Expenditures
-¥1.5B
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
-32%
|
|
|
Takara Bio Inc
TSE:4974
|
Capital Expenditures
-¥12.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-8%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Capital Expenditures
-¥405m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-40%
|
|
J
|
Japan Tissue Engineering Co Ltd
TSE:7774
|
Capital Expenditures
-¥273.2m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-23%
|
See Also
What is Modalis Therapeutics Corp's Capital Expenditures?
Capital Expenditures
-39.7m
JPY
Based on the financial report for Dec 31, 2023, Modalis Therapeutics Corp's Capital Expenditures amounts to -39.7m JPY.
What is Modalis Therapeutics Corp's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-136%
Over the last year, the Capital Expenditures growth was 80%. The average annual Capital Expenditures growth rates for Modalis Therapeutics Corp have been 64% over the past three years , -136% over the past five years .
You don't have any saved screeners yet
